| Galectins and their ligands: amplifiers, silencers or tuners of the inflammatory response? GA Rabinovich, LG Baum, N Tinari, R Paganelli, C Natoli, FT Liu, ... Trends in immunology 23 (6), 313-320, 2002 | 635 | 2002 |
| Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. P Patrignani, MR Panara, A Greco, O Fusco, C Natoli, S Iacobelli, ... Journal of Pharmacology and Experimental Therapeutics 271 (3), 1705-1712, 1994 | 617 | 1994 |
| Concentrations of galectin-3 in the sera of normal controls and cancer patients I Iurisci, N Tinari, C Natoli, D Angelucci, E Cianchetti, S Iacobelli Clinical cancer research 6 (4), 1389-1393, 2000 | 362 | 2000 |
| Galectin‐3 overexpression protects from apoptosis by improving cell adhesion properties P Matarrese, O Fusco, N Tinari, C Natoli, FT Liu, ML Semeraro, W Malorni, ... International journal of cancer 85 (4), 545-554, 2000 | 299 | 2000 |
| The secreted tumor-associated antigen 90K is a potent immune stimulator. A Ullrich, I Sures, M D'Egidio, B Jallal, TJ Powell, R Herbst, A Dreps, ... Journal of Biological Chemistry 269 (28), 18401-18407, 1994 | 206 | 1994 |
| 90K (Mac-2 BP) and galectins in tumor progression and metastasis A Grassadonia, N Tinari, I Iurisci, E Piccolo, A Cumashi, P Innominato, ... Glycoconjugate journal 19 (7-9), 551-556, 2002 | 183 | 2002 |
| Galectin‐3 overexpression protects from cell damage and death by influencing mitochondrial homeostasis P Matarrese, N Tinari, ML Semeraro, C Natoli, S Iacobelli, W Malorni FEBS letters 473 (3), 311-315, 2000 | 172 | 2000 |
| Prognostic value of a novel circulating serum 90K antigen in breast cancer S Iacobelli, P Sismondi, M Giai, M d'Egidio, N Tinari, C Amatetti, ... British journal of cancer 69 (1), 172-176, 1994 | 126 | 1994 |
| PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis F Passiglia, G Bronte, V Bazan, C Natoli, S Rizzo, A Galvano, A Listì, ... Oncotarget 7 (15), 19738, 2016 | 123 | 2016 |
| Gynaecomastia with cimetidine GF Delle Fave, G Tamburrano, L De Magistris, C Natoli, ML Santoro, ... The Lancet 309 (8025), 1319, 1977 | 117 | 1977 |
| Molecular mechanisms of endocrine resistance and their implication in the therapy of breast cancer M Zilli, A Grassadonia, N Tinari, A Di Giacobbe, S Gildetti, J Giampietro, ... Biochimica et Biophysica Acta (BBA)-Reviews on Cancer 1795 (1), 62-81, 2009 | 91 | 2009 |
| A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable A Cortellini, M Bersanelli, S Buti, K Cannita, D Santini, F Perrone, R Giusti, ... Journal for immunotherapy of cancer 7 (1), 57, 2019 | 90 | 2019 |
| Triple positive breast cancer: a distinct subtype? P Vici, L Pizzuti, C Natoli, T Gamucci, L Di Lauro, M Barba, D Sergi, ... Cancer treatment reviews 41 (2), 69-76, 2015 | 88 | 2015 |
| Elevated serum levels of 90K/MAC-2 BP predict unresponsiveness to α-interferon therapy in chronic HCV hepatitis patients M Artini, C Natoli, N Tinari, A Costanzo, R Marinelli, C Balsano, P Porcari, ... Journal of hepatology 25 (2), 212-217, 1996 | 87 | 1996 |
| Targeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer: hope or reality from clinical studies P Vici, L Pizzuti, L Mariani, G Zampa, D Santini, L Di Lauro, T Gamucci, ... Expert review of vaccines 15 (10), 1327-1336, 2016 | 62 | 2016 |
| Measurement of a breast cancer associated antigen detected by monoclonal antibody SP-2 in sera of cancer patients S Iacobelli, E Arno, P Sismondi, C Natoli, N Gentiloni, G Scambia, M Giai, ... Breast cancer research and treatment 11 (1), 19-30, 1988 | 61 | 1988 |
| Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts A Cumashi, N Tinari, C Rossi, R Lattanzio, C Natoli, M Piantelli, ... Cancer letters 270 (2), 229-233, 2008 | 60 | 2008 |
| Lack of expression of galectin-3 is associated with a poor outcome in node-negative patients with laryngeal squamous-cell carcinoma M Piantelli, S Iacobelli, G Almadori, M Iezzi, N Tinari, C Natoli, G Cadoni, ... Journal of clinical oncology 20 (18), 3850-3856, 2002 | 60 | 2002 |
| Adhesion to 90K (Mac-2 BP) as a mechanism for lymphoma drug resistance in vivo B Fornarini, C D'Ambrosio, C Natoli, N Tinari, V Silingardi, S Iacobelli Blood, The Journal of the American Society of Hematology 96 (9), 3282-3285, 2000 | 59 | 2000 |
| Synthetic inhibitors of galectin-1 and-3 selectively modulate homotypic cell aggregation and tumor cell apoptosis IDA Iurisci, A Cumashi, AA Sherman, YE Tsvetkov, N Tinari, E Piccolo, ... Anticancer research 29 (1), 403-410, 2009 | 58 | 2009 |
valentina iacobelliSapienza University of RomeEmail verificata su unich.it
